The DOI matches its Crossref record.
Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma.
Abstract
Previously untreated adult patients who presented with advanced diffuse large-cell lymphoma (DLCL) at diagnosis were studied to identify possible prognostic factors. One hundred five patients were seen between 1974 and 1981; 45 patients were stage III and 60 patients were stage IV. All patients received cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-Bleo). Stage III patients also received radiation therapy alternated with chemotherapy. Overall survival was 50% at 5 years and 43% at 8 years. Seventy-four patients achieved a complete remission (CR) and 37 are alive and disease-free with a median follow-up of 72 months. There was no difference in clinical outcome between stage III and stage IV. However, a proportional hazards model identified lactic dehydrogenase (LDH) level and tumor burden, among all clinical factors studied, as independent risk factors for survival. These two factors were also important for achievement of remission and relapse-free survival. Three distinct patient risk groups were identified with 5-year survival rates of 87%, 48%, and 20%, respectively. The measure of tumor burden proposed herein, along with LDH level, can be used for developing treatment programs, and for meaningful comparison of different treatment regimens, as well as assessment of prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,949
The Liver Tumor Segmentation Benchmark (LiTS)
Bilic, P., Christ, P., Li, H. B., Vorontsov, E., Ben-Cohen, A., Kaissis, G., Szeskin, A., Jacobs, C., Mamani, G. E. H., Chartrand, G., et al. (2023) · Medical Image Analysis · doi:10.1016/j.media.2022.102680 · Cited by 1,412
The Liver Tumor Segmentation Benchmark (LiTS)
Bilic, P., Christ, P., Li, H. B., Vorontsov, E., Ben-Cohen, A., Kaissis, G., Szeskin, A., Jacobs, C., Mamani, G. E. H., Chartrand, G., et al. (2019) · arXiv · doi:10.48550/arxiv.1901.04056 · Cited by 1,412
Kwak, L. W., Halpern, J., Olshen, R. A., & Horning, S. J. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.6.963 · Cited by 431
Treatment of Non-Hodgkin's Lymphoma
Wood, A. J. J., & Armitage, J. O. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304083281409 · Cited by 376
Metadata
- Authors
- Jagannath, S., Velasquez, W. S., Tucker, S. L., Fuller, L. M., McLaughlin, P. W., Manning, J. T., North, L. B., & Cabanillas, F. C.
- Venue
- Journal of Clinical Oncology
- Published
- 1986-06
- Volume
- 4
- Issue
- 6
- Pages
- 859-865
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1962291688
- Cited by
- 186
- References
- 0
- FWCI
- 9.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. https://app.cochat.ai/papers/10.1200/jco.1986.4.6.859
- The paper
- Jagannath, S., Velasquez, W. S., Tucker, S. L., Fuller, L. M., McLaughlin, P. W., Manning, J. T., North, L. B., & Cabanillas, F. C. (1986). Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1986.4.6.859
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.